Rhythm Pharmaceuticals
Markets IMCIVREE and develops MC4R agonists for rare neuroendocrine obesity disorders.
$107.17
After-hours close−0.10 (−0.09%)
At close$107.27(−4.67%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 123.66%Insiders 0.80%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 68.59M · Float 55.93M · 81.5% free float
Institutions13F, as of Jun 30, 2026
311 holders · 84.83M shares · 65 new positions · 173 increased · 99 reduced · 46 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 6.67M | 9.72% | 0 | Aug 14, 2026 |
| BlackRock, Inc. | 6.16M | 8.98% | −80.2K | Aug 7, 2026 |
| Baker Bros. Advisors LP | 5.60M | 8.17% | 0 | Aug 14, 2026 |
| Primecap Management Co/CA/ | 3.17M | 4.62% | −248.7K | Aug 14, 2026 |
| Vanguard Portfolio Management LLC | 3.14M | 4.57% | +96.2K | Aug 13, 2026 |
| Vanguard Capital Management LLC | 3.01M | 4.38% | +38.2K | Aug 13, 2026 |
| JPMorgan Chase & Co | 2.65M | 3.87% | +1.10M | Aug 12, 2026 |
| Perceptive Advisors LLC | 2.59M | 3.77% | +212.5K | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| RA Capital Management, L.P. | 9.90% | 6.67M | 13G | Feb 17, 2026 ↗ |
| Baker Bros. Advisors LP | 8.90% | 5.60M | 13G | May 15, 2025 ↗ |
| BlackRock, Inc. | 6.90% | 4.36M | 13G | Apr 24, 2025 ↗ |
| Primecap Management Co/CA/ | 5.21% | 3.48M | 13G | Feb 12, 2026 ↗ |
| Perceptive Advisors LLC | 5.10% | 3.52M | 13G | May 15, 2026 ↗ |
| Vanguard Capital Management | 5.02% | 3.43M | 13G | Apr 30, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| David P. Meeker | director, officer: President and CEO | 239.0K | 0.35% | Feb 3, 2026 |
| Hunter C. Smith | officer: Chief Financial Officer | 119.6K | 0.17% | May 20, 2026 |
| Yann Mazabraud | officer: EVP, Head of International | 55.7K | 0.08% | Aug 14, 2026 |
| Pamela J. Cramer | officer: Chief Human Resources Officer | 29.4K | 0.04% | Feb 3, 2026 |
| Edward T. Mathers | director | 21.2K | 0.03% | Mar 16, 2026 |
| Joseph Shulman | officer: Chief Technical Officer | 15.9K | 0.02% | Aug 17, 2026 |
| Stuart A. Arbuckle | director | 11.7K | 0.02% | Jun 25, 2026 |
| Jennifer L. Good | director | 11.7K | 0.02% | Jun 25, 2026 |
| Christophe Jean | director | 11.7K | 0.02% | Jun 25, 2026 |
| David W. J. Mcgirr | director | 11.7K | 0.02% | Jun 25, 2026 |
17 ten-percent owners hold 26.16M shares by Form 4, outside the officers-and-directors figure above · 7 people have not refiled in the last 18 months (1.69M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 13, 2026 | Alastair Garfieldofficer: Chief Scientific Officer | Sale · 4 lots | 7,763 | $117.57 | 2,295 |
| Aug 13, 2026 | Joseph Shulmanofficer: Chief Technical Officer | Sale | 5,079 | $119.75 | 15,915 |
| Aug 13, 2026 | Jennifer Kayden Leeofficer: EVP, Head of North America | Sale | 75,834 | $117.38 | 0 |
| Aug 12, 2026 | Yann Mazabraudofficer: EVP, Head of International | Sale · 6 lots | 57,000 | $116.15 | 55,655 |
| Jun 22, 2026 | Lynn A. Tetraultdirector | Sale | 37,000 | $100.32 | 7,000 |
| May 15, 2026 | Christopher Paul Germanofficer: Corporate Controller & CAO | Sale | 4,643 | $92.21 | 0 |
| Mar 4, 2026 | Christopher Paul Germanofficer: Corporate Controller & CAO | Sale | 5,614 | $89.56 | 160 |
| Feb 19, 2026 | Hunter C. Smithofficer: Chief Financial Officer | Sale · 4 lots | 4,385 | $101.26 | 110,512 |
| Feb 17, 2026 | Hunter C. Smithofficer: Chief Financial Officer | Sale · 5 lots | 3,569 | $101.38 | 114,897 |
| Feb 12, 2026 | Hunter C. Smithofficer: Chief Financial Officer | Sale · 4 lots | 1,592 | $98.23 | 118,466 |
CongressHouse and Senate disclosures
Not reported.